首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1574655

全球癌症抗體藥物複合物市場：市場規模、藥物批准、價格、銷售和臨床試驗的見解（2030）

Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030

出版日期: 2024年10月01日 | 出版商:

KuicK Research | 英文 1300 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

抗體藥物複合物（ADC）已成為癌症治療中的創新治療劑，它將單株抗體的特異性與細胞毒性藥物的功效相結合。這種創新療法由透過穩定連接體與細胞毒性藥物結合的抗體組成，可針對癌細胞，同時最大限度地減少對周圍健康組織的損害。抗體藥物複合物的快速發展反映了它們在臨床和商業上的成功，目前有16個產品在各個市場獲得批准，銷售額預計將在2023年達到100億美元，並在2024年首次達到6個月內超過70億美元。這種成長凸顯了抗體藥物複合物是更廣泛的癌症藥物市場中商業上可行的部分，並推動了研究和開發工作，以創造更有效和安全的候選化合物。

截至2024年 10月，全球監管機構已批准 16 種抗體藥物複合物，其中 13 種目前可用於臨床用於治療各種癌症類型。其中，代表性的有Padceb、Kadcyla、Enherz等，2023年將佔抗體藥物複合物總銷售額的60%左右。 Enhertu 適用於治療多種 HER2 陽性實體腫瘤，而 Padcev 和 Kadcyla 僅分別被批准用於治療膀胱癌和乳癌。這些產品類型顯示市場對 ADC 的治療潛力以及治療各種癌症類型的有效性越來越有信心。

全球癌症抗體藥物複合物市場的特點是競爭格局，針對包括實體腫瘤和血液惡性腫瘤在內的多種癌症的積極發展。然而，其中肺癌目前的開發活動最為廣泛，有超過60個候選藥物處於臨床試驗中，包括CAB-AXL-ADC、TQB2102和MYTX-011，其中一個Enhertu已經獲得批准。這反映出肺癌治療的策略轉變，肺癌仍然是全球癌症死亡的主要原因之一，並且有很高的未滿足的醫療需求。抗體-藥物複合物有可能提供更有效、毒性更小的治療選擇，並且在該治療領域特別有吸引力。

功能	詳細資料
關鍵片段	應用：癌症類型、區域、技術平台
涵蓋的適應症	目標疾病：肺癌、乳癌、子宮頸癌、胰臟癌、食道癌等
主要目標國	美國、中國、韓國、加拿大、印度等
目標藥	Enhertu、Adcetris、Polivy、Kadcyla 等
報告範圍	作用模式、ADC生成、管道和批准的藥物見解、銷售見解、當前趨勢、未來機會、市場驅動因素和挑戰
目標公司	Biocytogen、Merck、AstraZeneca、Pfizer、Daiichi Sankyo、ADC Therapeutics等

本報告調查了全球癌症抗體藥物複合物市場，並提供了市場概況以及藥物趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司的競爭格局。

Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
Approved Cancer Antibody Drug Conjugates: 16 Drugs
Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage & Price Analysis
Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
Insight On Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

Features	Details
Key Segments:	Application by Cancer Type, By Region, Technology Platforms
Indications Covered:	Lung Cancer, Breast Cancer, Cervical Cancer, Pancreatic Cancer, Pancreatic Cancer, Esophageal Cancer, among others
Key Countries Covered:	US, China, South Korea, Canada, India, among others
Drugs Covered:	Enhertu, Adcetris, Polivy, Kadcyla, among others
Report Coverage:	Mechanism of Action, ADC Generations, Pipeline & Approved Drugs Insight, Sales Insight, Current Trends, Future Opportunities, Market Drivers & Challenges
Companies Covered:	Biocytogen, Merck, AstraZeneca, Pfizer, Daiichi Sankyo, ADC Therapeutics, among others

Antibody drug conjugates (ADCs) have emerged as a transformative class of therapeutics in the cancer treatment landscape, integrating the specificity of monoclonal antibodies with the potency of cytotoxic drugs. These innovative therapies consist of an antibody linked to a cytotoxic agent through a stable linker, allowing targeted delivery to cancer cells while minimizing damage to surrounding healthy tissues. The rapid evolution of antibody drug conjugates reflects their clinical and commercial success, with 16 products currently approved across various markets and sales surpassing US$ 10 Billion in 2023 and US$ 7 Billion in the first 6 months of 2024. This growth highlights antibody drug conjugates as a commercially viable segment of the broader cancer therapeutics market, prompting increased research and development efforts to create more effective and safer candidates.

As of October 2024, regulatory authorities around the world have approved 16 antibody drug conjugates, with 13 currently available for clinical use for different cancer types. Among these, prominent examples include Padcev, Kadcyla, and Enhertu, which collectively accounted for approximately 60% of the total antibody drug conjugates sales in 2023. While Enhertu is indicated for the treatment of several HER2-positive solid cancers, Padcev and Kadcyla are solely approved for the treatment of bladder cancer and breast cancer, respectively. The commercialization of these products demonstrates not only their therapeutic potential but also the market's growing confidence in the effectiveness of ADCs in managing various cancer types.

Global cancer antibody drug conjugates market is characterized by a competitive landscape, with substantial development efforts targeting multiple cancers, including both solid tumors and hematological malignancies. However, out of all these, lung cancer is currently witnessing the most extensive development activity, with over 60 candidates in clinical trials, including CAB-AXL-ADC, TQB2102, and MYTX-011, and one Enhertu, approved for use in clinical setting. This reflects a strategic shift towards addressing the high-unmet medical need in lung cancer, which remains one of the leading causes of cancer mortality worldwide. The potential for antibody drug conjugates to provide more effective and less toxic treatment options makes them particularly attractive in this therapeutic area.

In contrast, however, breast cancer has experienced the highest number of antibody drug conjugates approvals to date, with four approved candidates, contributing significantly to the market's commercial success. Two key players in this domain are the aforementioned Kadcyla and Enhertu, both of which have demonstrated remarkable efficacy and have achieved significant sales milestones. The promising pipeline also includes AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan, a TROP2-directed antibody drug conjugate that is currently under review for its use in breast cancer treatment. This continued investment in research and development underscores the critical role antibody drug conjugates play in advancing cancer care.

Regionally, the cancer antibody drug conjugates market is primarily led by the US and China, two of the largest and most dynamic pharmaceutical markets globally. In the US, robust healthcare infrastructure, high R&D expenditure, and a favorable regulatory environment foster innovation and accelerate the approval process for new therapies. Additionally, the presence of major pharmaceutical companies, such as Regeneron, Gilead, Merck and Pfizer, bolsters the competitive landscape, enabling rapid development and commercialization of antibody drug conjugates.

In China, the growing demand for advanced cancer treatments, coupled with increasing government support for biotechnology and pharmaceutical research, has catalyzed significant growth in the antibody drug conjugates sector. Local players like Mabwell, Miracogen, Chia Tai Tianqing Pharmaceutical, Hansoh BioMedical, Sichuan Baili Pharmaceuticals, Biocytogen and Affinity Biopharma are emerging as significant contributors to the market, developing novel Antibody drug conjugates tailored to the specific needs of the Chinese patient population, and out licensing promising candidates to their international counterparts through license agreements.

The global market for cancer antibody drug conjugates represents a dynamic and rapidly evolving segment of the cancer therapeutics landscape. With ongoing clinical trials, innovative research, and increasing regulatory support, antibody drug conjugates are poised to play an increasingly pivotal role in cancer treatment. As efforts continue to address existing challenges and expand the range of approved indications, the future of antibody drug conjugates appears promising, offering hope to patients worldwide in the fight against cancer. The collaborative efforts among pharmaceutical companies, regulatory bodies, and research institutions will be crucial in shaping the next wave of advancements in this exciting therapeutic field.

1. Introduction To Antibody Drug Conjugates

1.1 Overview
1.2 Mechanism of Antibody Drug Conjugates

2. Antibody Drug Conjugates As Cancer Targeted Therapy

2.1 Applications of Antibody Drug Conjugates in Cancer
2.2 Advantages of Antibody Drug Conjugates
2.3 Comparison of Antibody Drug Conjugates With Traditional Therapies

3. Generations of Antibody Drug Conjugates

3.1 Antibody Drug Conjugates - Evolution
3.2 Next Generation Antibody Drug Conjugates Prospects

4. Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

5. Global Cancer Antibody Drug Conjugates Clinical Trials Overview

5.1 By Phase
5.2 By Indication
5.3 By Company
5.4 By Patient Segment
5.5 By Country

6. Global Cancer Antibody Drug Conjugates Market Outlook

6.1 Current Market Scenario
6.2 Future Growth Avenues

7. Global Cancer Antibody Drug Conjugates Research & Market Trends by Region

7.1 US
7.2 China
7.3 Europe
7.4 South Korea
7.5 Australia
7.6 UK
7.7 Canada
7.8 Japan
7.9 India
7.10 Latin America

8. Global Cancer Antibody Drug Conjugates Market Trends & Development By Indications

8.1 Lung Cancer
8.2 Breast cancer
8.3 Leukemia
8.4 Ovarian Cancer
8.5 Gastrointestinal Cancer
8.6 Lymphoma
8.7 Urogenital Cancer
8.8 Cervical Cancer
8.9 Head & Neck Cancer
8.10 Brain Cancer
8.11 Prostate cancer
8.12 Pancreatic Cancer
8.13 Skin cancer
8.14 Esophageal cancer

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

10.1 Mylotarg
- 10.1.1 Availability & Patent Insight
- 10.1.2 Pricing & Dosage Insight
10.2 Adcetris
- 10.2.1 Availability & Patent Insight
- 10.2.2 Pricing & Dosage Insight
10.3 Kadcyla
- 10.3.1 Availability & Patent Insight
- 10.3.2 Pricing & Dosage Insight
10.4 Besponsa
- 10.4.1 Availability & Patent Insight
- 10.4.2 Pricing & Dosage Insight
10.5 Lumoxiti (Market Withdrawal In 2023)
- 10.5.1 Availability & Patent Insight
- 10.5.2 Pricing & Dosage Insight
10.6 Polivy
- 10.6.1 Availability & Patent Insight
- 10.6.2 Pricing & Dosage Insight
10.7 Padcev
- 10.7.1 Availability & Patent Insight
- 10.7.2 Pricing & Dosage Insight
10.8 Enhertu
- 10.8.1 Availability & Patent Insight
- 10.8.2 Pricing & Dosage Insight
10.9 Trodelvy
- 10.9.1 Availability & Patent Insight
- 10.9.2 Pricing & Dosage Insight
10.10 Blenrep (Partial Market Withdrawal In 2023)
- 10.10.1 Availability & Patent Insight
- 10.10.2 Pricing & Dosage Insight
10.11 Zynlonta
- 10.11.1 Availability & Patent Insight
- 10.11.2 Pricing & Dosage Insight
10.12 Tivdak
- 10.12.1 Availability & Patent Insight
- 10.12.2 Pricing & Dosage Insight
10.13 Elahere
- 10.13.1 Availability & Patent Insight
- 10.13.2 Pricing & Dosage Insight
10.14 Ujvira
- 10.14.1 Availability & Patent Insight
- 10.14.2 Pricing & Dosage Insight
10.15 Akalux
- 10.15.1 Availability & Patent Insight
- 10.15.2 Pricing & Dosage Insight
10.16 Aidixi
- 10.16.1 Availability Insight

11. Approved Cancer Antibody Drug Conjugates - Sales Insights & Forecast 2028

11.1 Adcetris
11.2 Padcev
11.3 Tivdak
11.4 Polivy
11.5 Kadcyla
11.6 Besponsa
11.7 Enhertu
11.8 Trodelvy
11.9 Zynlonta
11.10 Elahere
11.11 Blenrep

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

12.1 Research
12.2 Preclinical
12.3 Phase I
12.4 Phase I/II
12.5 Phase II
12.6 Phase II/III
12.7 Phase III
12.8 Preregistration

13. Marketed Cancer Antibody Drug Conjugates Clinical Insight By Company, Country & Indication

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview

15.1 Key Market Growth Drivers
15.2 Challenges For Market Growth

16. Competitive Landscape

16.1 Biocytogen
16.2 Bristol Myers Squibb
16.3 Eli Lilly
16.4 Innovent Biologics
16.5 Merck
16.6 Pfizer
16.7 Affinity Biopharma
16.8 Biokin
16.9 Synaffix
16.10 ADC Therapeutics
16.11 AstraZeneca
16.12 Daiichi Sankyo
16.13 Duality Biologics
16.14 Immunogen
16.15 LigaChem Biosciences

簡介目錄圖表

List of Figures

Figure 1-1: Antibody Drug Conjugates - General Working Mechanism
Figure 2-1: Advantages of Antibody Drug Conjugates
Figure 3-1: Antibody-Drug Conjugates - Approval by Generation
Figure 3-2: Cancer Antibody Drug Conjugates - Opportunities for Next-Generation Development
Figure 5-1: Global - Cancer Antibody Drug Conjugates In Clinical Trials By Phase, 2024 Till 2030
Figure 5-2: Global- Cancer Antibody Drug Conjugates In Clinical Trials By Indication, 2024 Till 2030
Figure 5-3: Global - Cancer Antibody Drug Conjugates In Clinical Trials By Company, 2024 Till 2030
Figure 5-4: Global - Cancer Antibody Drug Conjugates In Clinical Trials By Patient Segment, 2024 Till 2030
Figure 5-5: Global - Cancer Antibody Drug Conjugates In Clinical Pipeline By Country, 2024 Till 2030
Figure 6-1: Global - Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2024
Figure 6-2: Global -Cancer Antibody Drug Conjugates Sales by Drug (US$ Million), Q1'2024
Figure 6-3: Global - Cancer Antibody Drug Conjugates Sales by Drug (US$ Million), Q2'2024
Figure 6-4: Global - Cancer Antibody Drug Conjugates Sales by Drug (US$ Million), H1'2024
Figure 6-5: Global - Cancer Antibody Drug Conjugates Market Share by Drugs (%), H1'2024
Figure 6-6: Global - Cancer Antibody Drug Conjugates Market (US$ Million), Q1 & Q2'2024
Figure 6-7: Global - Cancer Antibody Drug Conjugates Market by Drug (US$ Million), 2023
Figure 6-8: Global - Cancer Antibody Drug Conjugates Market Share by Drugs (%), 2023
Figure 6-9: Global - Cancer Antibody Drug Conjugates Market (US$ Million), Q1-Q4'2023
Figure 6-10: Global - Cancer Antibody Drug Conjugates Market Forecast (US$ Billion), 2024 - 2030
Figure 7-1: Daiichi Sankyo DXd ADC Technology - Clinical Candidates
Figure 7-2: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), October'2024
Figure 8-1: Datopotamab Deruxtecan Phase 3 (NCT04656652) Study - Initiation & Completion Year
Figure 8-2: Luveltamab tazevibulin Phase 2 (NCT06555263) Study - Initiation & Completion Year
Figure 8-3: Ifinatamab Deruxtecan Phase 3 (NCT06203210) Study - Initiation & Completion Year
Figure 8-4: Sigvotatug Vedotin Phase 3 (NCT06012435) Study - Initiation & Completion Year
Figure 8-5: Sacituzumab Tirumotecan Phase 3 (NCT06074588) Study - Initiation & Completion Year
Figure 8-6: Datopotamab deruxtecan Phase 3 (NCT05104866) Study - Initiation & Completion Year
Figure 8-7: Datopotamab deruxtecan Phase 3 (NCT06112379) Study - Initiation & Completion Year
Figure 8-8: TQB2102 Phase 3 (NCT06561607) Study - Initiation & Completion Year
Figure 8-9: ORM-5029 Phase 1 (NCT05511844) Study - Initiation & Completion Year
Figure 8-10: BMS-986497 Phase 1 (NCT06419634) Study - Initiation & Completion Year
Figure 8-11: JBH492 Phase 1 (NCT04240704) Study - Initiation & Completion Year
Figure 8-12: Rinatabart sesutecan Phase 3 (NCT06619236) Study - Initiation & Completion Year
Figure 8-13: Luveltamab tazevibulin Phase 2/3 (NCT05870748) Study - Initiation & Completion Year
Figure 8-14: Raludotatug Deruxtecan (R-DXd) Phase 2/3 (NCT06161025) Study - Initiation & Completion Year
Figure 8-15: AZD5335 Phase 1/2 (NCT05797168) Study - Initiation & Completion Year
Figure 8-16: Dato-DXd Phase 2 (NCT05489211) Study - Initiation & Completion Year
Figure 8-17: IKS014 Phase 1 (NCT05872295) Study - Initiation & Completion Year
Figure 8-18: AZD0901 Phase 2 (NCT06219941) Study - Initiation & Completion Year
Figure 8-19: Polatuzumab Vedotin Phase 2 (NCT05410418) Study - Initiation & Completion Year
Figure 8-20: Loncastuximab tesirine Phase 2 (NCT05453396) Study - Initiation & Completion Year
Figure 8-21: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
Figure 8-22: Zilovertamab vedotin Phase 1/2 (NCT06395103) Study - Initiation & Completion Year
Figure 8-23: Padcev Phase 2 (NCT05775471) Study - Initiation & Completion Year
Figure 8-24: Trodelvy Phase 2 (NCT05581589) Study - Initiation & Completion Year
Figure 8-25: BL-B01D1 Phase 2 (NCT05785039) Study - Initiation & Completion Year
Figure 8-26: 9MW2821 Phase 3 (NCT06196736) Study - Initiation & Completion Year
Figure 8-27: Trodelvy Phase 2 (NCT05838521) Study - Initiation & Completion Year
Figure 8-28: Enhertu Phase 2 (NCT04482309) Study - Initiation & Completion Year
Figure 8-29: 9MW2821 Phase 1/2 (NCT05216965) Study - Initiation & Completion Year
Figure 8-30: Aidixi Phase 2 (NCT06003231) Study - Initiation & Completion Year
Figure 8-31: Padcev Phase 2 (NCT04225117) Study - Initiation & Completion Year
Figure 8-32: Ozuriftamab vedotin Phase 1/2 (NCT03504488) Study - Initiation & Completion Year
Figure 8-33: Panitumumab-IRDye800 Phase 1/2 (NCT03510208) Study - Initiation & Completion Year
Figure 8-34: Patritumab deruxtecan (HER3-DXd) Phase 2 (NCT05865990) Study - Initiation & Completion Year
Figure 8-35: Trodelvy Phase 2 (NCT03725761) Study - Initiation & Completion Year
Figure 8-36: HS-20093 Phase 2 (NCT06001255) Study - Initiation & Completion Year
Figure 8-37: FOR46 Phase 1b/2 (NCT05011188) Study - Initiation & Completion Year
Figure 8-38: ARX517 Phase 1 (NCT04662580) Study - Initiation & Completion Year
Figure 8-39: Pancreatic Ductal Adenocarcinoma - Prevalence Compared to Other Pancreatic Cancer Types
Figure 8-40: SOT102 Phase 1/2 (NCT05525286) Study - Initiation & Completion Year
Figure 8-41: TORL-2-307 Phase 1 (NCT05156866) Study - Initiation & Completion Year
Figure 8-42: EBC-129 Phase 1 (NCT05701527) Study - Initiation & Completion Year
Figure 8-43: Panitumumab-IRDye800 Phase 1/2 (NCT03384238) Study - Initiation & Completion Year
Figure 8-44: Ozuriftamab vedotin Phase 1/2 (NCT03504488) Study - Initiation & Completion Year
Figure 8-45: Vobramitamab duocarmazine (MGC018) Phase 1 (NCT05293496) Study - Initiation & Completion Year
Figure 8-46: AMT253 Phase 1/2 (NCT06209580) Study - Initiation & Completion Year
Figure 8-47: Zirconium Zr 89 Crefmirlimab Berdoxam Phase 2 (NCT05013099) Study - Initiation & Completion Year
Figure 8-48: Enhertu Phase 2 (NCT05480384) Study - Initiation & Completion Year
Figure 8-49: HS-20093 Phase 2 (NCT06112704) Study - Initiation & Completion Year
Figure 8-50: DP303c Phase 1/2 (NCT06577376) Study - Initiation & Completion Year
Figure 9-1: Proprietary ADC Technology - Seagen
Figure 9-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
Figure 9-3: TRAAC- Tallac Therapeutics
Figure 9-4: ATAC- Heidelberg Pharma
Figure 9-5: Tub-tag(R) & P5 - Tubulis
Figure 10-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
Figure 10-2: Mylotarg - Approval Year by Region
Figure 10-3: Mylotarg - Cost of 4.5 mg Supply in US (US$), October'2024
Figure 10-4: Mylotarg - Cost of 5 mg Supply in UK (US$), October'2024
Figure 10-5: US - Adcetris FDA Approval Year by Indication
Figure 10-6: Adcetris - Approval Year by Region
Figure 10-7: Japan - Adcetris PMDA Approval Year by Indication
Figure 10-8: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 10-9: Adcetris - Patent Expiration by Region
Figure 10-10: Adcetris - Cost of 50 mg Supply in US & UK (US$), October'2024
Figure 10-11: US - Kadcyla FDA Approval Year by Indication
Figure 10-12: Kadcyla - Approval Year by Region
Figure 10-13: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 10-14: Kadcyla - Cost of Supply in US, Europe & UK (US$), October'2024
Figure 10-15: Kadcyla - Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
Figure 10-16: Besponsa - Approval Year by Region
Figure 10-17: Besponsa - Cost of 0.9 mg Supply in US, October'2024
Figure 10-18: Besponsa - Cost of 1 mg Supply in Europe & UK (US$), October'2024
Figure 10-19: Lumoxiti - Orphan Designation Years
Figure 10-20: Lumoxiti - Patent Expiry Years
Figure 10-21: Lumoxiti - Cost of 1 mg Supply in US & Europe (US$), October'2024
Figure 10-22: Polivy - Approval Year by Region
Figure 10-23: Polivy - Orphan Drug Designation Approval Year by Region
Figure 10-24: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
Figure 10-25: Polivy - Cost of 140 mg Supply in Europe (US$), October'2024
Figure 10-26: Polivy - Cost of 30 & 140 mg Supply in US & UK (US$), October'2024
Figure 10-27: Padcev - Approval Year by Region
Figure 10-28: US - Padcev FDA Approval & Patent Expiration Year
Figure 10-29: Padcev - Cost of 20 & 30 mg Supply In US & Europe (US$), October'2024
Figure 10-30: Enhertu - Approval Year by Region
Figure 10-31: US - Polivy FDA Approval Year by Indication
Figure 10-32: Enhertu - FDA Orphan Drug Designation & Exclusivity Expiration Year
Figure 10-33: Enhertu - Cost of 100 mg Supply In US, Europe & UK (US$), October'2024
Figure 10-34: US - Trodelvy FDA Approval by Indication
Figure 10-35: Trodelvy - Approval Year by Region
Figure 10-36: Trodelvy - Patent Expiration by Region
Figure 10-37: Trodelvy - Cost of 180 mg Supply In US & UK (US$), October'2024
Figure 10-38: Trodelvy - Cost of 180 & 200 mg Supply In Europe (US$), October'2024
Figure 10-39: Blenrep - FDA & EMA Orphan Drug Designations
Figure 10-40: Blenrep - FDA & EMA Approval
Figure 10-41: Zynlonta - FDA & EMA Approval Years
Figure 10-42: Zynlonta - FDA & EMA Orphan Drug Designation Years
Figure 10-43: Zynlonta - Cost of 10 mg Supply In US, Europe & UK (US$), October'2024
Figure 10-44: Tivdak - Cost of 40 mg Supply In US & Europe (US$), October'2024
Figure 10-45: Elahere - Cost of Unit & Supply In US (US$), October'2024
Figure 10-46: Ujvira - Cost of 100 mg & 160 mg Supply (US$), October'2024
Figure 10-47: Akalux - Sakigake Designation & PMDA Approval Year
Figure 10-48: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
Figure 11-1: Adcetris - Global Annual Sales (US$ Million), 2020-2024
Figure 11-2: Adcetris - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
Figure 11-3: Adcetris - Global Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-4: Padcev - Global Annual Sales (US$ Million), 2020-2024
Figure 11-5: Padcev - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
Figure 11-6: Padcev - Global Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-7: Tivdak - Global Annual Sales (US$ Million), 2021-2024
Figure 11-8: Tivdak - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
Figure 11-9: Tivdak - Global Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-10: Polivy - Global Sales Values (US$ Million), 2020-2024
Figure 11-11: Polivy - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2024
Figure 11-12: Polivy - Global Sales By Region (%), H1'2024
Figure 11-13: Polivy - US Annual Sales Values (US$ Million), 2020-2024
Figure 11-14: Polivy - US Quarterly Sales Values (US$ Million), Q1 & Q2'2024
Figure 11-15: Polivy - Europe Annual Sales Values (US$ Million), 2020-2024
Figure 11-16: Polivy - Europe Quarterly Sales Values (US$ Million), Q1 & Q2'2024
Figure 11-17: Polivy - Japan Annual Sales Values (US$ Million), 2020-2024
Figure 11-18: Polivy - Global Sales By Region (US$ Million), Q1-Q4'2023
Figure 11-19: Polivy - Global Sales By Region (%), 2023
Figure 11-20: Polivy - Global Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-21: Polivy - US Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-22: Polivy - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-23: Polivy - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-24: Polivy - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-25: Kadcyla - Global Sales Values (US$ Million), 2020-2024
Figure 11-26: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2024
Figure 11-27: Kadcyla - Global Sales By Region (%), H1'2024
Figure 11-28: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-29: Kadcyla - Global Sales By Region (US$ Million), Q1-Q4'2023
Figure 11-30: Kadcyla - Global Sales By Region (%), 2023
Figure 11-31: Kadcyla - US Annual Sales Values (US$ Million), 2020-2024
Figure 11-32: Kadcyla - US Quarterly Sales Values (US$ Million), Q1 & Q2'2024
Figure 11-33: Kadcyla - US Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-34: Kadcyla - Europe Annual Sales Values (US$ Million), 2020-2024
Figure 11-35: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1 & Q2'2024
Figure 11-36: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-37: Kadcyla - Japan Annual Sales Values (US$ Million), 2020-2024
Figure 11-38: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2024
Figure 11-39: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-40: Kadcyla - ROW Annual Sales Values (US$ Million), 2020-2024
Figure 11-41: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2024
Figure 11-42: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2023
Figure 11-43: Besponsa - Global Annual Sales (US$ Million), 2020-2023
Figure 11-44: Besponsa - Global Sales by Region (US$ Million), 2023
Figure 11-45: Besponsa - Quarterly Sales by Region (%), 2023
Figure 11-46: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-47: Besponsa - US Annual Sales (US$ Million), 2020-2023
Figure 11-48: Besponsa - Europe Quarterly Sales (US$ Million), 2022
Figure 11-49: Besponsa - ROW Quarterly Sales (US$ Million), 2022
Figure 11-50: Enhertu - Global Annual Sales (US$ Million), 2020-2024
Figure 11-51: Enhertu - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2024
Figure 11-52: Enhertu - Global Quarterly Sales (US$ Million), 2022
Figure 11-53: Trodelvy - Global Annual Sales (US$ Million), 2020-2024
Figure 11-54: Trodelvy - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
Figure 11-55: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-56: Trodelvy - Annual Sales By Region (US$ Million), 2023
Figure 11-57: Trodelvy - Annual Sales By Region (%), 2023
Figure 11-58: Trodelvy - US Annual Sales (US$ Million), 2020-2024
Figure 11-59: Trodelvy - US Quarterly Sales (US$ Million), Q1 & Q2'2024
Figure 11-60: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-61: Trodelvy - Europe Annual Sales (US$ Million), 2020-2024
Figure 11-62: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 & Q2'2024
Figure 11-63: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-64: Trodelvy - ROW Annual Sales (US$ Million), 2020-2024
Figure 11-65: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 & Q2'2024
Figure 11-66: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-67: Zynlonta - Global Annual Sales (US$ Million), 2021-2024
Figure 11-68: Zynlonta - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
Figure 11-69: Zynlonta - Global Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-70: Elahere - Global Annual Sales (US$ Million), 2022-2024
Figure 11-71: Elahere - Global Quarterly Sales (US$ Million), Q1 & Q2'2024
Figure 11-72: Elahere - Global Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 11-73: Blenrep - Global Annual Sales (US$ Million), 2020-2023
Figure 11-74: Blenrep - Europe Quarterly Sales Value (US$ Million), Q1-Q4'2023
Figure 14-1: Antibody Drug Conjugate Combinations in Studies
Figure 14-2: Approved Antibody Drug Conjugate Combinations

List of Tables

Table 3-1: First Generation Antibody Drug Conjugates - Examples
Table 3-2: Second Generation Antibody Drug Conjugates - Examples
Table 3-3: Third Generation Antibody Drug Conjugates - Examples
Table 3-4: Fourth Generation Antibody Drug Conjugates - Examples
Table 4-1: Approved Antibody Drug Conjugates
Table 6-1: Cancer Antibody Drug Conjugates Market - Recent Acquisition Deals
Table 6-2: Cancer Antibody Drug Conjugates - Recent Collaborations
Table 6-3: Cancer Antibody Drug Conjugates - Companies Securing Funding for Clinical Development
Table 6-4: Cancer Antibody Drug Conjugates - Companies Announcing Plans for Manufacturing Facilities
Table 6-5: Cancer Antibody Drug Conjugates - Recent Regulatory Designations
Table 6-6: Cancer Antibody Drug Conjugates - Recent IND Clearances
Table 7-1: US - Approved Cancer Antibody Drug Conjugates, October'2024
Table 7-2: US - Antibody Drug Conjugate Under FDA Review, October'2024
Table 7-3: China - Approved Antibody Drug Conjugates, October'2024
Table 7-4: EU - Approved Cancer Antibody Drug Conjugates, October'2024
Table 7-5: Australia - Approved Cancer Antibody Drug Conjugates, October'2024
Table 7-6: Canada - Approved Cancer Antibody Drug Conjugates, October'2024
Table 7-7: Japan - Approved Cancer Antibody Drug Conjugates, October'2024
Table 8-1: Lung Cancer - Approved Antibody Drug Conjugates
Table 8-2: Breast Cancer - Approved Antibody Drug Conjugates
Table 8-3: Leukemia - Approved Antibody Drug Conjugates
Table 8-4: Ovarian Cancer - Approved Antibody Drug Conjugate
Table 8-5: Gastrointestinal Cancer - Approved Antibody Drug Conjugates
Table 8-6: Lymphoma - Approved Antibody Drug Conjugates
Table 8-7: Urogenital Cancer - Approved Antibody Drug Conjugates
Table 8-8: Cervical Cancer - Approved Antibody Drug Conjugates
Table 8-9: Head & Neck Cancer - Approved Antibody Drug Conjugates
Table 10-1: Adcetris - Recommended Dosage
Table 14-1: Antibody Drug Conjugate Combinations - Ongoing Clinical Trials